

**Pediatric CIRB Meeting Agenda**

**June 8, 2023**

---

**I. Continuing Review**

**ANHL2121**, Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis (Version Date 01/27/23)

---

**II. Continuing Review**

**ARET2121**, Intravitreal Melphalan for Intraocular Retinoblastoma (Version Date 08/26/22)

---

**III. Continuing Review**

**PED-CITN-02**, GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma and Neuroblastoma to Increase Systemic Tumor Exposure (Version Date 05/18/23)

---

**IV. Continuing Review**

**PEPN1924**, A Phase 2 Study of DS-8201A (NSC# 807708, IND# 153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma (Version Date 12/22/21)

---